Clinical Trial Update: Dose Escalation Study of MLN4924 in Adults With Melanoma [Phase 1]

View source ↗

Summary

Clinical trial update for a Phase 1 dose-escalation study of MLN4924 (pevonedistat) in adults with metastatic melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MLN4924 (pevonedistat)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Metastatic Melanoma | Phase 1 | Status: COMPLETED